You have been married for eleven years. You know the sound of your husband's truck in the driveway and you know, now, the particular silence that means it was a bad day. You have read about ketamine therapy for depression. You also know that if you bring it up the wrong way, the silence will get longer.
Partners carry a specific kind of worry into this conversation. A survey our publisher commissioned offers some evidence about what to expect.
What 443 adults said first
Our June 2026 survey gave 443 people in ten Midwest states five ways to describe how ketamine treatment for depression or PTSD first strikes them. Here is how they split in the final validated data:
- 34 percent: cautious, though open to it
- 18 percent: hopeful, or at least curious
- 21 percent: skeptical of it
- 18 percent: the idea was brand new to them
- 9 percent: negative
Read that list the way a partner might. The single largest group was willing to consider it while wanting to be careful. Taken together with the hopeful group, open-leaning respondents came to 51 percent. The group that would likely shut the conversation down was under one in ten.
What that does and does not mean for you
These are general findings from ordinary adults in the Midwest. They are not a forecast of how your spouse will respond. Married people were not singled out. Husbands, wives, partners and the wider family of veterans or first responders were: that group of 156 leaned open at 57 percent. What the numbers offer is perspective: the reaction you dread, a hard no, was the least common answer in the survey.
That perspective can change how you prepare. You do not need a debate strategy. You need patience and good information.
Why "cautious" deserves respect
A cautious spouse is not being stubborn. Ketamine has a complicated reputation. It is an anesthetic, sometimes a street drug, and lately the subject of online companies selling home treatment. Wariness is a sensible response to that mix.
The approved version is more tightly controlled than many people realize. Esketamine, brand name Spravato, is a nasal spray with an FDA label for two groups of grown-ups: those whose depression keeps resisting treatment, and those in a major depressive episode marked by acute suicidal thoughts or actions. Only certified centers may give it. After every dose the patient sits for two hours or more with staff keeping watch. None of it goes home in a bag.
That is a different thing from IV ketamine infusions or at-home ketamine lozenges, both off-label for depression. Regulators at the FDA have spoken out about home use that nobody supervises. Explaining these differences clearly, without pressure, is often exactly what a cautious person needs. Brain Recovery Centers has an explanation of the supervised Spravato process you could read first.
The never-heard-of-it group
Nearly one in five respondents did not have a reaction because the idea was new. When we asked specifically about Spravato, unfamiliarity was even more widespread: 73 percent were hearing the name for the first time, while a scant 6 percent knew enough to explain it.
If your partner falls into that group, the conversation starts at the very beginning. "Did you know there's an approved treatment for depression that won't budge on regular medication?" is a question, not a proposal. It lets them get curious before anyone is asked to decide anything.
Where partners fit in the decision
Our survey asked whose advice would most likely get someone to go through with this kind of care. Their own doctor, answered 74 percent. Friends and relatives, the category a spouse falls into, drew 18 percent.
For partners, that is both humbling and freeing. Humbling because the final word will not be yours. Freeing because you do not have to. Your most powerful move is usually to help your spouse get in front of a doctor and ask the question.
The need you are seeing is common
If it feels like you are alone in this, the survey suggests otherwise. Asked about depression, anxiety, or PTSD that ordinary medicine failed to ease, 72 percent of respondents said it had touched them, a person they love, or both. For 22 percent it was only the person they love, which is the seat you are in. Across the Midwest, a lot of people are sitting where you are sitting.
Six percent of respondents also told us their husband, wife, or partner is a veteran or a first responder. If that is your household, the medical questions are the same, but work schedules, privacy at work, and coverage through TRICARE or an employer plan may shape the practical path.
Turning the numbers into a conversation
- Pick a calm time. A drive, a walk, or a quiet evening, not the aftermath of a fight.
- Start with what you see. "You've been working so hard at this, and it still seems heavy. How are you really doing?"
- Ask before you inform. "I read about something. Can I tell you about it?"
- Name the limits. Say plainly that it does not work for everyone, is not for everyone, and has side effects.
- Point to the doctor. "Would you be willing to ask your doctor whether it makes sense for you?"
- Offer something concrete. Rides, childcare, calling the insurance company, sitting in the waiting room.
- Accept the answer, for now. A "not yet" leaves the door open.
What only a clinician can say
Whether your spouse is a candidate for esketamine depends on their history, their other conditions, and their medications. High blood pressure, certain blood vessel problems, and other factors can rule it out. This article is about how people react and how to talk, not about whether any treatment suits your partner.
Do not hold this conversation for a better moment if your partner has spoken of not wanting to be alive, or if you are scared for their safety. Phone or text 988 now; a spouse who is scared is exactly who the Suicide and Crisis Lifeline was built to help, any hour, and a counselor will help you choose the next step.
Methodology
The publisher of this site commissioned this survey and covered the bill; it went out over the Pollfish consumer panel and finished on June 23, 2026. Its 443 completed responses came from people 18 to 64 in Illinois, Minnesota, Kansas, Missouri, Indiana, Nebraska, Iowa, Wisconsin, Ohio, and Oklahoma. These are final, validated figures; spouses alone were too few to report.